Upstate Active Clinical Trials

Study Title:

Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

What is the purpose of the study? (in Layman's terms, please describe the study)

We are doing the second part of this study because we want to find out if radiation therapy with docetaxel and cetuximab or radiation therapy with cisplatin and an immunotherapy drug, atezolizumab, is better than the usual approach for your high-risk head and neck cancer. The usual approach is defined as care most people get for high-risk head and neck cancer.

Upstate Institutional Review Board (IRB) Number:

501348

Study/Protocol ID:

RTOG-1216

Study Phase:

II/III

Patient Age Group:

Adults

Principal Investigator:

Seung Shin Hahn, MD

What is involved if I participate?

• How long is the study?
  10 years
• Is transportation provided or reimbursed?
  No
• Is parking provided or reimbursed?
  Yes
• What tests and procedures are involved?
  Usual approach of radiation therapy with cisplatin chemotherapy OR
  Radiation therapy with docetaxel and cetuximab chemotherapy OR
  Radiation therapy with cisplatin chemotherapy and the study drug, atezolizumab

Where will the study take place?

Downtown Cancer Center
Community Cancer Center
Verona Medical Oncology and Radiation Oncology
Oswego Medical Oncology and Radiation Oncology
The Hill Medical Center Radiation Oncology

Other Information:

https://clinicaltrials.gov/study/NCT01810913

ClinicalTrials.Gov ID:

NCT01810913

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Laine Abernathy
Phone: 315-464-6528
Email: [email protected]

Return to Previous Page || Search Again